REPLY: Go Reply and Sprint Reply Automate the Creation of Clinical Study Reports for Dr. Willmar Schwabe with AI

Business Wire
02-21
By combining Go Reply's expertise in Google technologies with Sprint Reply’s ability to transform business models, a cutting-edge solution has been created that allows Dr. Willmar Schwabe's team to focus on what really matters: advancing research for innovative medicines to improve public health. (Graphic: Business Wire)

TURIN, Italy, February 21, 2025--(BUSINESS WIRE)--Go Reply, a leading Google Cloud Premier Partner, together with Sprint Reply, the Reply Group’s expert in strategic consulting and digital transformation, has developed an AI-driven tool for the pharmaceutical company Dr. Willmar Schwabe that streamlines the preparation of clinical study reports and ensures compliance with the highest scientific standards.

To obtain marketing authorisation for its high-quality herbal drugs, Dr. Willmar Schwabe must rigorously test their efficacy, safety and tolerability in clinical trials. By leveraging the power of Google Cloud and its Large Language Model (LLM) Gemini, the tool developed by Go Reply and Sprint Reply significantly simplifies the traditionally time-consuming process of creation of the final reports from these clinical trials. Using pre-defined prompts, staff no longer need to manually summarise all the results, which are often meticulously documented over 1,000 pages and can efficiently generate detailed report sections that fully comply with the International Council for Harmonisation (ICH) standards.

"Developing an AI-based solution for a medical writing task together with Reply is a milestone for us," stated Dirk Bredenbröker, Executive Vice President Research & Development at Dr. Willmar Schwabe. "By working with the experts at Go Reply and Sprint Reply, we have now developed a better understanding of the potential of AI and how it can be used profitably in different areas."

By combining Go Reply's expertise in Google technologies with Sprint Reply’s ability to transform business models, a cutting-edge solution has been created that allows Dr. Willmar Schwabe's team to focus on what really matters: advancing research for innovative medicines to improve public health.

Go Reply
Go Reply, as part of the Reply Group, is a Google Cloud Premier Partner offering services in the following areas: Cloud Strategy and Migration, Cloud Hosting, Big Data, Machine Learning, Generative AI, PCI/ISO Compliance and Security Management, Productivity Services and fully managed services around the clock that support business-critical applications. www.go-reply.com

Sprint Reply
Sprint Reply specialises in strategic consulting, innovation and digital transformation. We support large and medium-sized companies in all industries in developing new and digital business opportunities. We are your partner for your current and future digital challenges. With our implementation-oriented approach, we help our clients to become digital pioneers in their respective industries. www.sprint-reply.de

Dr. Willmar Schwabe
Dr. Willmar Schwabe is a global leader in the production and research of herbal medicinal products with over 150 years of experience. As a traditional family-owned company based in Karlsruhe, Dr. Willmar Schwabe focuses on scientific research, standardisation and continuous improvement of herbal preparations. With over 4,000 employees worldwide, including around 1,400 in Germany, the company is committed to the highest quality and innovation in phytotherapy. Dr. Willmar Schwabe products are based on patented plant extracts and clinically proven efficacy to sustainably promote people's health. www.schwabe-group.com/en

View source version on businesswire.com: https://www.businesswire.com/news/home/20250221805824/en/

Contacts

Media contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Phone +390117711594



Irene Caia
i.caia@reply.com
Tel. +39 02 535761

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10